Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 13/20 | 0.64 |
| ▸ | AKT1 | P31749 | 9/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780589 | 0.79 | AKT2 (1.00) | AKT2AKT1ROCK2AKT3KCNH2 | |
| SCHEMBL1003219 | 0.76 | HTR2C (0.50) | AKT2PRKACA | |
| SCHEMBL1000995 | 0.76 | AKT2 (0.59) | AKT2CYP2C9 | |
| SCHEMBL3492169 | 0.76 | AKT2 (0.44) | AKT2AKT1ROCK2AKT3KCNH2 | |
| SCHEMBL2783501 | 0.76 | AKT2 (0.65) | AKT2AKT1ROCK2AKT3KCNH2 | |
| SCHEMBL2780797 | 0.74 | AKT2 (0.67) | AKT2AKT1ROCK2AKT3KCNH2 | |
| SCHEMBL2780731 | 0.74 | AKT2 (0.77) | AKT2AKT1ROCK2AKT3KCNH2 | |
| SCHEMBL1002593 | 0.74 | AKT2 (0.57) | AKT2AKT1PRKACA | |
| SCHEMBL13343968 | 0.74 | LIMK2 (0.53) | AKT2ROCK2PRKACA | |
| SCHEMBL27746374 | 0.73 | PRKACA (0.47) | AKT2AKT1ROCK2AKT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | claimed |
| CN-101627042-A | Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety | ASTEX THERAPEUTICS LTD | 2010-01-13 | — | — | CN | claimed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | claimed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| CN-101627042-A | Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety | ASTEX THERAPEUTICS LTD | 2010-01-13 | — | — | CN | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | AKT2 27/4885AKT1 40/4885ROCK2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.